𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗥𝗮𝘁𝗶𝗼: $XBI / $IBB Weekly. $XBI equal-weight, whereas $IBB is cap-weighted. This gives $XBI an advantage when smaller bio surges (typical during "risk on"). Does $XBI catch up to $IBB? Or does this backtest hold 🤔
Featured chart from GuruHaven 🤓
As long as my line stay green adding on dip this week is an opportunity to profit early in Spring ( seeded time for #biotech is now)
but mostly trading on daily base , today I wait longer 3-4 days perhaps
EYPT chart is building up for another run. Potential catalyst before year end with an sNDA for Short Duration Yutiq. accumulation has been slow and steady indicating EYPT oversold conditions.
weekly chart --> Harmonic Gartley (bounced off significant support level) and been in uptrend since.
Symmetrical Triangle/ Breakout setup has been known to...
Biotech buyouts have been very strong, especially with Gene therapy stocks as of late.
Bounced off Lower end of channel
bounced off 1.618 fib extension along with important reversal leg of Elliott Wave Theory.
if price holds inside the lower end of the channel there is a potential move back up and test the gap.
looking for nice $0.40+ swing...
This technical analysis was conducted using the Swing•Genie Cycles swing trading indicator on a 2-day chart. It typically takes between 1 and 10 days from the time the Swing•Genie Cycles indicator prints a dot on the chart for the trend to demonstrably change. A green dot is a bullish signal, a red dot is a bearish signal. Swing trades using this system typically...
WIth Warren and Bernie fading a bit, Bio/health have jumped nicely. Too much too soon IMO, at the minimum a short term pull back is coming. I am hoping we can become more range bound in the technicals and return to cyclical trading between 78 and 87, this type of cycle is great IBB and XBI, however getting caught when it breaks down can hurt! I use XBI has my...
As the month of October begins and broader markets sold off, Biotech sectors are still negative/ flat for the year. Market headlines from high prescription drug prices and lawsuits regarding the opioid epidemic have plagued some of the IBB's largest holdings; which have held biotech ETF's down while the S&P reached all time highs.
Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here.
Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float.
Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame.
Follow me on twitter and instagram...
One of my followers asked (and this has never happened before) for me to comment on LABU. I was touched by the request and so I have responded, and this after having a website which I shut down with 10,000 hits a month never once did anyone ask me to comment on a stock. My strength has always been analysis and dissection so I am happy to oblige.
After a recent selloff in mid June 2019, Stock price went from from $6.70 down to $3.44. Cala looks to have established a double bottom. New strong uptrend suggests it has potentially capitulated from the selloff making these levels very attractive for any investors who are sidelined and looking for a good technical/ fundamental trade in biotech. Cala looks to be...
Long-Term pattern suggests that after previous dilution, Eyepoint's stock price went range bound for quite awhile before breaking out.
This marks potential accumulation range for anyone looking to build a position in EYPT.
Ranges make for good swing trade positions (especially 20%+ both ways) and a way to average down.
Range low/ highs, range from $1.42 - $1.87...